<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851461</url>
  </required_header>
  <id_info>
    <org_study_id>ID11-50-17</org_study_id>
    <nct_id>NCT00851461</nct_id>
  </id_info>
  <brief_title>Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy</brief_title>
  <official_title>Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy in Thai Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a therapeutic trial study to demonstrate whether Goserelin, a LHRH agonist has
      benefit in SBMA

      Objective:

        1. To study effects of Goserelin to clinical course of patients with spinal and bulbar
           muscular atrophy in Thailand

        2. To demonstrate physiological and pathological changes in treated patients with
           Goserelin.

        3. To assess tolerability and adverse effect of Goserelin therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle power</measure>
    <time_frame>every 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>electrophysiologic study (Nerve conduction and Electromyogram)</measure>
    <time_frame>every 3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Spinobulbar Muscular Atrophy</condition>
  <condition>Kennedy's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>Goserelin 10.8 mg SC every 3 months</description>
    <other_name>Zoladex LA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Electrophysiologic study</intervention_name>
    <description>Nerve conduction study Electromyogram</description>
    <other_name>NCV</other_name>
    <other_name>EMG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tissue biopsy</intervention_name>
    <description>skin and muscle biopsy before and after treatment every year</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent

          2. Males, age over 20 years, undesired fertility

          3. Have positive family history of muscle weakness with these clinical signs:

               -  bulbar involvement (difficulty in breathing, swallowing, talking)

               -  muscle atrophy with or without fasciculation

               -  decrease or normal deep tendon reflex

               -  normal Babinski response

               -  no sensory impairment

               -  mild tremor (either postural or intention)

               -  gynecomastia

               -  decrease libido and infertility

          4. Subjects have a confirmed diagnosis to SBMA by both NCV test and DNA study
             demonstrated the number of CAG repeated more than 35.

        Exclusion Criteria:

          1. Have weakness caused by other etiologies and have liver or kidney disease.

          2. Have currently prostatic cancer

          3. Want to have a child

          4. Participation in a clinical study during the last 30 days.

          5. Females and children age &lt; 20 years old
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanyachau Sura, M.D., MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramathibodi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Genetics and Molecular Medicine Unit,, Department of Medicine, Ramathibodi Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dean of Ramathibodi Hospital</name_title>
    <organization>Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand</organization>
  </responsible_party>
  <keyword>Spinobulbar muscular atrophy</keyword>
  <keyword>Kennedy's disease</keyword>
  <keyword>Goserelin</keyword>
  <keyword>Electrophysiologic study</keyword>
  <keyword>Inclusion body</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Disorders, Atrophic</mesh_term>
    <mesh_term>Bulbo-Spinal Atrophy, X-Linked</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

